Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Dermatology
•
Cutaneous Lymphomas
Would you consider using a JAK inhibitor for CTCL?
Related Questions
Would you give adjuvant radiation after complete resection of a small primary cutaneous follicular lymphoma of the scalp?
After achieving clinical response to bexarotene for cutaneous lymphoma (e.g., MF stage Ib or FMF), do you wean to the lowest dose for sustained remission, and if so, when?
Can hypogammaglobulinemia cause a false negative DIF in bullous disease?
Do you consider JAK inhibitors, such as baricitinib, a reasonable option for FFA?
How often do you recommend ophthalmologic screening exams for patients with sarcoidosis?
What factors do you weigh most heavily in the selection of radiotherapy versus topical treatments for lentigo maligna in a patient who is not a surgical candidate?
Have you utilized JAK inhibitors in patients on dialysis?
What is your approach to diagnosing and managing methotrexate-induced alopecia?
Have you encountered idiopathic aseptic facial granuloma in areas other than the face?
What additional workup do you pursue in a patient in whom you suspect Yellow Nail Syndrome?
